Symptom Management and Therapeutic Support

Rengalin provides symptomatic support for cough associated with acute infectious and inflammatory diseases of the upper and lower respiratory tract, including conditions such as influenza, SARS, acute pharyngitis, and laryngotracheitis.

The medicine is commonly used for cough associated with acute respiratory tract infections. A key benefit is its relevance for easing symptoms whether the cough is dry and irritating or has transitioned into a productive, wet phase. This may assist with supporting patients during episodes where cough manifestations change.

In chronic contexts, the medicine is commonly used to help with the ongoing symptomatic burden of conditions like chronic bronchitis, COPD, and postnasal drip syndrome, supporting patients with cough symptoms in these conditions. It contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.

Quick Fact: Symptom Support
Symptom Focus	Dry, irritative cough and productive, wet cough
Conditions	Acute ARI, influenza, SARS, Chronic Bronchitis, COPD
Benefit	Supports easing of daytime and nocturnal symptom burden

Eligibility and Contraindications

Ренгалин’s eligibility profile strictly defines the permitted user population based on official regulatory mandates. The medicine is contraindicated for several specific groups and requires conditional use for others.

Absolute contraindications prohibit its use in individuals with known hypersensitivity to any active component or excipient. Use is also strictly prohibited in patients diagnosed with the metabolic condition Hereditary Fructose Intolerance.

Age-Based Eligibility

Population	Regulatory Status
Adults and Children	Permitted (Age 3 years)
Children	Contraindicated (Age < 3 years)

The pediatric population under three years of age is officially excluded from use.

Pregnancy and Lactation Status

For individuals who are breastfeeding (lactation), eligibility is conditional: use is only permitted if the anticipated benefit to the mother outweighs the potential risk to the child, as safety data in this population has not been formally established. Specific prohibitions or conditions for use during pregnancy are not explicitly documented in the available official labeling. The label does not document explicit restrictions concerning use in patients with severe renal or hepatic impairment.

The official regulatory documents define the interaction profile of Ренгалин based on the expected behavior of a release-active compound. The primary regulatory finding is that there are no cases of incompatibility with other medicinal products registered up to the present time. This official statement confirms the potential for pharmacodynamic compatibility when the product is co-administered with other symptomatic agents often used for cough, such as mucolytics, expectorants, and other non-narcotic antitussives.

Due to the unique nature of its affinity-purified antibody components, the drug is not expected to be involved in conventional pharmacokinetic interactions. Official regulatory documents contain no data detailing the inhibition or induction of the cytochrome P450 enzyme system or specific effects on drug transporters (e.g., P-glycoprotein). Therefore, the likelihood of Ренгалин altering the clearance or systemic exposure of most co-administered small-molecule drugs is considered low, and the need for dose adjustments related to such interactions is not officially documented.

Regarding interactions with non-medicinal products, the regulatory label imposes a timing-based restriction related to food. Administration of the product is formally required to take place not during a meal. No specific restrictions or documented interactions are provided for alcohol, specific foods, or herbal products. The overall regulatory structure establishes constraints focused on the timing of administration rather than on prohibitive substance combinations.

How Ренгалин Works

Ренгалин acts via affinity-purified antibodies that functionally modulate three key endogenous signaling molecules: bradykinin, histamine, and endogenous morphine. This multi-target mechanism modulates signaling within pathways corresponding to the central and peripheral components of the cough reflex.

---

Modulating Peripheral Irritation and Sensory Signals

This domain focuses on the peripheral action of the drug through bradykinin and histamine pathways. The mechanism modifies the functional activity of these inflammatory mediators, altering the signaling characteristics of sensory C-fibers in the airways. This action alters the signaling threshold of peripheral sensory nerves and modulates the afferent (input) signal pathway of the cough reflex.

---

Adjusting Central Cough Reflex Control

This component relates to the drug's influence on the endogenous opioid system to modulate activity in the medullary cough center. By affecting molecules related to endogenous morphine, the mechanism modulates the central neural excitability. This modulation influences the processing unit that generates the cough motor pattern, resulting in an adjustment of the central components of the reflex.

The administration of Ренгалин follows specific procedural instructions. The medicine is supplied as a tablet for oral dissolution and as an oral solution.

Administration Scope

Instruction Category	Detail
Route of administration	Oral route.
Dosing schedule	The general regimen uses a single dose (1 tablet or 5–10 ml solution) administered three times a day. For acute, severe symptoms, frequency may be intensified to four to six times a day for the first three days. Specific 4-week courses using 2 tablets three times a day may also be used.
Timing in relation to meals	Administration is directed to occur without meals (outside of scheduled mealtimes).
Preparation requirements	The tablets must be held in the mouth until full dissolution and should not be swallowed whole. The score line is not intended for dividing the dose.
Age-group administration rules	Approved for use in adults and pediatric patients starting from 3 years of age.
Special procedural conditions	For the oral solution, it is advised to hold the liquid briefly in the mouth before swallowing.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral administration requiring mucosal contact (oral/sublingual dissolution).
Frequency pattern	Daily use with a variable frequency (three times daily standard, four to six times daily for initial acute phase).
Use-context constraints	The total duration of the course is not fixed but is guided by the severity and progress of the clinical condition.

---

Connection to the overall use protocol: The instructions establish a standardized oral procedure where the complete dissolution of the tablet in the mouth is required for proper administration, distinguishing it from conventional swallowing. This regimen is defined by a standard daily frequency with a permitted, short-term intensification for acute symptom periods. The overall protocol emphasizes that the course length is not fixed but is guided by the specific clinical context.

Research evidence / Overview of studies for Ренгалин

1. Evidence for Acute Cough in Respiratory Infections

Research has examined the use of Ренгалин in conditions characterized by acute, episodic cough, such as those associated with upper respiratory tract infections (URIs) like pharyngitis, laryngitis, and tracheitis. This evidence base relies primarily on short-term, randomized clinical trials (RCTs), some of which were placebo-controlled and others that compared the medicine to other active comparator medicines.

These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and daily functioning. Researchers measured changes in cough intensity using standardized scoring systems over a defined time interval, typically around seven days. Trials also assessed patient-reported outcomes describing perceived discomfort, such as the quality of sleep, and monitored the time it took for the cough to evolve or reach a pre-defined level of resolution.

2. Evidence for Persistent Cough in Chronic Obstructive Pulmonary Disease (COPD)

Dedicated multicenter, randomized, placebo-controlled trials explored the use of Ренгалин in the context of this indication. The study explored outcomes reflecting daily functioning or activity level in adults with stable COPD who were already receiving their standard maintenance therapy but still had ongoing cough symptoms. Research examined changes in cough severity scores and evaluated functional measures, such as the COPD Assessment Test (CAT) score, which describes the overall burden of the disease on a patient's life.

3. Evidence in Special Populations

Research has explored the use of Ренгалин in conditions characterized by acute, episodic cough, such as those associated with upper respiratory tract infections (URIs) like pharyngitis, laryngitis, and tracheitis. The clinical trial program for acute cough included children in a broad age range, from as young as six months to 17 years old. Similarly, older adults were included in the research for the COPD indication. While these studies help show what has been observed so far in these groups, evidence remains limited for certain subgroups, such as pregnant or breastfeeding individuals.

4. Long-Term Evidence and Follow-up Duration

The evidence base is characterized by relatively short follow-up durations. For acute cough associated with URIs, treatment and observation periods were limited, typically not exceeding 14 days. In the studies related to persistent cough in COPD, the primary assessment period was four weeks.

5. Evidence Gaps and Areas of Ongoing Research

A key limitation is that many of the published clinical trials and research programs were conducted within a specific geographic area (e.g., Russia). This regional focus limits the broad applicability of the findings. Comparative evidence against all relevant international treatments is still emerging. Additionally, data for certain groups remain insufficient.

Key Studies & References

1. Study Details | NCT07171099 | Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children (Special Population Study Registration)

Common questions about Ренгалин (FAQ)

---

Q: How many days does the treatment with Rengalin last on average?

A: The official protocol states that the duration of therapy is not fixed and is determined by a physician based on the severity and progress of the clinical condition.

In clinical research examining the medicine's use for acute cough, treatment and observation periods typically spanned up to 14 days. For persistent cough, research utilized a primary assessment period of four weeks.

---

Q: Does Rengalin have an interaction with alcohol?

A: Official regulatory documents do not provide specific restrictions or documented interactions for Rengalin with alcohol, specific foods, or herbal products.

The only official constraint regarding consumption is the requirement that the medicine be administered outside of scheduled mealtimes.

---

Q: Can Rengalin be taken during pregnancy or breastfeeding?

A: Official regulatory labeling does not document explicit restrictions or prohibitions for the use of Rengalin during pregnancy.

For breastfeeding (lactation), official labeling notes that use is only permitted when the anticipated benefit to the mother is considered to outweigh the potential risk to the child, given that safety data for this population is limited.

---

Q: Can Rengalin be taken if there are stomach problems?

A: Official contraindications specifically prohibit the use of Rengalin in individuals with the metabolic condition Hereditary Fructose Intolerance.

There are no other explicit contraindications or restrictions documented in the official labeling regarding the use of the medicine for other general stomach or gastric issues.

---

Q: Does Rengalin really have an evidence base?

A: The medicine's evidence base is described in official information and includes short-term, randomized clinical trials (RCTs) examining its use in acute cough associated with respiratory tract infections, and in persistent cough associated with Chronic Obstructive Pulmonary Disease (COPD).

---

Q: Does Rengalin affect driving?

A: The clinical safety assessment documented a 'zero factor' for side effects reliably related to the study medication during clinical trials.

Official documents do not specifically list effects, such as sedation or drowsiness, that would impair a patient's ability to safely drive or operate machinery.

---

Q: Is Rengalin an antibiotic or not?

A: According to official documentation, Rengalin is not classified as an antibiotic.

It is described as a Combination Antitussive Agent that belongs to the specialized pharmacological group of release-active compounds.

---

Q: Can Rengalin be given to children?

A: Official guidelines indicate that the medicine is approved for use in pediatric patients starting from 3 years of age.

Use of Rengalin is officially contraindicated for children who are younger than three years old.

---

Q: Can Rengalin and cough syrups be combined?

A: Official documents confirm that pharmacodynamic compatibility is expected when Rengalin is co-administered with other symptomatic agents often used for cough.

This includes medicines such as mucolytics (to thin mucus) and expectorants (to help clear airways).

---

Q: How is Rengalin different from other throat and cough medicines?

A: The medicine is defined by its unique composition of three distinct affinity-purified antibodies (to bradykinin, histamine, and morphine).

This non-conventional pharmacological approach provides a dual mechanism of action, intended to modulate both the peripheral sensory signals and the central cough reflex control.

---

Q: Is it true that Rengalin can cause drowsiness?

A: Data from regulatory-backed clinical investigations documented a 'zero factor' for side effects reliably related to the study medication.

This means no adverse reactions, including drowsiness or sedation, were recorded during the official assessment that could be directly attributed to the drug.

---

Q: Is Rengalin only for dry cough or for wet cough too?

A: Rengalin is clinically recognized for its ability to address both non-productive (dry) and productive (wet) cough types.

Its strategic formulation aims to provide a balanced modulation of the complex cough reflex across different stages of a respiratory tract irritation.

---

Q: Does Rengalin help with a scratchy throat?

A: The mechanism of action is described as modulating peripheral irritation and sensory signals in the airways.

The research evidence for Rengalin focuses on cough associated with infections like pharyngitis and laryngitis, conditions which commonly involve throat irritation.

---

Q: What happens if you accidentally take more Rengalin than indicated?

A: Official documentation does not contain specific information regarding the outcomes of accidental overdose.

However, the general safety profile noted during clinical assessment reported a 'zero factor' for side effects and documented no serious adverse reactions.

---

Q: How do I know that Rengalin is not suitable for me?

A: The primary absolute contraindication is a known hypersensitivity (allergic reaction) to any of the active components or excipients contained in the tablet or oral solution formulation.

This potential for an allergic reaction is the main safety constraint defining suitability.

---

Q: Is it necessary to follow a diet while being treated with Rengalin?

A: The regulatory label imposes a timing-based restriction that requires the product to be administered outside of scheduled mealtimes (without meals).

Beyond this timing constraint, no specific dietary restrictions are provided or documented in the official materials.

---

Q: Does Rengalin have any special conditions for use?

A: Official documentation outlines specific procedural conditions for the administration of the medicine.

This includes the requirement that tablets must be held in the mouth until fully dissolved and the oral solution should be held briefly in the mouth before swallowing.

---

Q: Can Rengalin help if the cough is already prolonged?

A: Research has explored the use of the medicine for persistent cough associated with chronic conditions.

Specifically, dedicated trials examined its use in the context of Chronic Obstructive Pulmonary Disease (COPD), with assessment periods lasting up to four weeks.

---

Q: Does Rengalin interact with anti-allergy drugs?

A: Official documents confirm that the medicine is compatible with other symptomatic agents, including anti-allergy drugs.

Due to its unique components, the likelihood of altering the clearance or systemic exposure of most co-administered small-molecule drugs is considered low.

How to Store and Dispose of Rengalin?

All storage and disposal requirements for Rengalin are defined by official governmental regulatory documentation to maintain product quality and safety.

Storage Constraint	Requirement
Maximum Temperature	Not exceeding 25 C
Environmental Protection	Protect from light
Packaging	Store in the original packaging
Child Safety	Keep out of the reach of children
Stability Limit	Do not use after the expiration date

Storage mandates require keeping the medicine within the specified temperature limit and safeguarding it from light exposure while ensuring it remains in its original container. Correct storage is necessary to preserve product stability until the labeled expiration date. For safety, the medicine must be stored out of the reach of children. Unused or expired Rengalin must be disposed of according to local regulations for pharmaceutical waste handling.